Project
IPSEN F-FR-60000-023
Ongoing - recruitment closed · 2020 until 2099
Aeppli Stefanie, Harder Anja, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2020
End Date
2099
Financing
Industry
Labels
kidney cancer
Brief description/objective
A Phase II Multicentre, Open-Labe- Study of Cabozantinib as 2nd Line Treatment in Subjects with unresectable, locally advanced Metastatic Renal Cell Carcinoma wiht a Clear- Cell Componentn who progressed after 1st Line Treatment with Checkpoint inhibitors.